Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126954891 | 12695489 | 1 | I | 20160824 | 20160829 | 20160829 | EXP | ES-JNJFOC-20160822452 | JANSSEN | DIAZ-CANEJA CM, PINA-CAMACHO L, GARCIA-AMADOR M, TAPIA-CASELLAS C, RODRIGUEZ-LATORRE P, SAIZ P, ET AL. INSULIN-RESISTANCE AND METABOLIC DISTURBANCES RELATED TO SECOND-GENERATION ANTIPSYCHOTICS IN A SAMPLE OF TREATMENT-NAIVE ADOLESCENTS COMPARED TO ADULTS. SCHIZOPHRENIA RESEARCH 2012;136:S257-S258. | 0.00 | Y | 0.00000 | 20160829 | OT | ES | ES |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126954891 | 12695489 | 1 | PS | RISPERIDONE. | RISPERIDONE | 1 | Unknown | U | U | 20272 | UNSPECIFIED |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126954891 | 12695489 | 1 | Product used for unknown indication |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126954891 | 12695489 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126954891 | 12695489 | Blood pressure systolic increased | |
126954891 | 12695489 | Dyslipidaemia | |
126954891 | 12695489 | Insulin resistance | |
126954891 | 12695489 | Metabolic syndrome | |
126954891 | 12695489 | Waist circumference increased | |
126954891 | 12695489 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |